110 studies on Melanocortin agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This review provides a strong evidence base for clinicians, confirming that pharmacologic interventions are safe and effective tools to improve sexual desire and satisfaction in individuals experiencing sexual dysfunc…
This review consolidates extensive research, providing a clear roadmap for future drug development targeting the melanocortin system. The identification of potent and selective ligands for MC3R and MC4R offers novel a…
This review profoundly underscores the immense and expanding potential of the central melanocortin system as a drug target for a wide array of metabolic and behavioral disorders. The established safety profile and cli…
This comprehensive review is crucial for advancing clinical practice in managing female sexual dysfunction, a condition affecting a significant number of women. By consolidating information on both established and nov…
If successful, the findings from this Phase 3 trial could demonstrate that Bremelanotide offers a significant new treatment option for premenopausal women suffering from HSDD, a condition with substantial impact on qu…
The provided clinical trial registration record, which concluded in May 2007, confirms that the study successfully completed its 8-week duration as planned. However, specific efficacy and safety results, including det…
This case report provides a crucial warning regarding the significant health risks associated with unregulated substances like Melanotan II nasal spray. It strongly implies that the use of such products can lead to se…